sábado, 31 de enero de 2015

Centers for Disease Control and Prevention (CDC) Health Matters for Women[TM] E-Newsletter Update

Centers for Disease Control and Prevention (CDC) Health Matters for Women[TM] E-Newsletter Update



Health Matters for Women newsletter from the CDC - US Department of Health and Human Services - Centers for Disease Control and Prevention

Health Matters for Women







New from CDC

Project Connect Implementation Guide
This evidence-based, scalable intervention is designed to increase youth access to sexual and reproductive health care services.
NIOSH Current Intelligence Bulletin: Reproductive Risks Associated With Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures
This bulletin reviews and summarizes all published studies on adverse reproductive effects of occupational exposures to antineoplastic drugs.
Prevalence of Reduced Muscle Strength in Older U.S. Adults: United States, 2011–2012
Muscle strength status did not differ by sex, except among persons aged 80 and over, where women had a higher prevalence of weak muscle strength than men.
 Births: Final Data for 2013
A total of 3,932,181 births were registered in the United States in 2013, down less than 1% from 2012.
WISEWOMAN Program Evaluation Toolkit, Clinical Linkages Brief, and Partnership Development Brief
The toolkit and briefs are intended to offer guidance and facilitate program planning and evaluation for WISEWOMAN program staff and a wide audience of individuals involved in related programs and issues.
Sexually Transmitted Disease Surveillance 2013
This report presents statistics and trends for sexually transmitted diseases in the United States through 2013.
#20Million Memorial
This online memorial honors an estimated 20 million deaths due to smoking – spouses, mothers, fathers, children, sisters, brothers, friends, – who we have lost.
Opioid Prescription Claims Among Women of Reproductive Age — United States, 2008–2012
Opioid-containing medications are widely prescribed among reproductive-aged women with either private insurance or Medicaid, with approximately one fourth of privately insured and over one third of Medicaid-enrolled women filling a prescription for an opioid each year during 2008–2012.
Public Health Grand Rounds: Understanding the Causes of Major Birth Defects: Steps to Prevention (video)
This Grand Rounds discussed some of the research underway to identify the risk factors for birth defects, and develop key intervention strategies to ensure that every child is born in the best possible health.
Worker Illness Related to Newly Marketed Pesticides — Douglas County, Washington, 2014
In this incident, off-target drift of a pesticide mixture was determined to be the cause of symptoms in 20 farmworkers (19 women and one man).
Understanding Evidence
The tool is an interactive Web resource that supports public health practitioners in making evidence-informed decisions around violence prevention.
CDC Says “Take 3” Actions to Fight The Flu
Flu is a serious contagious disease that can lead to hospitalization and even death. CDC urges you to take actions to protect yourself and others from influenza (the flu).
Chronic Disease Indicators
The 2015 CDI is an integrated source for a wide range of key indicators for the surveillance of chronic diseases, conditions, and risk factors. Eighteen topic categories and 124 indicators include women’s health conditions and risk factors, as well as social context.
Health Insurance Marketplace and Women
Enroll in a plan by February 15, 2015, get the preventive services you need, and navigate the health system to stay healthy.
Working Together to Stop HIV With The Positive Women’s Network – USA
The goals of the Summit were to build leadership skills; address critical policy, advocacy, and research issues; and foster a community among women living with HIV.
National Wear Red Day, Friday, February 6, 2015
Wear red on National Wear Red Day to help raise awareness about heart disease in women. Know the signs of a heart attack, ask your doctor questions about heart health, and learn how to lower your risk for heart disease.
2015 National HIV Prevention Conference
This four-day conference will include plenary sessions, workshops, roundtables and poster presentations and is a platform for conference participants to engage in rigorous scientific, programmatic, and technology information exchange.
Birth-18 Years & "Catch-up" Immunization Schedules, United States, 2015
Each year, the Advisory Committee on Immunization Practices publishes immunization schedules for persons age birth through 18 years.
Vital Signs: Alcohol Poisoning Deaths — United States, 2010–2012
During 2010–2012, an average of six deaths from alcohol poisoning occurred each day among persons aged ≥15 years in the United States.
Supplement Use and Other Characteristics Among Pregnant Women with a Previous Pregnancy Affected by a Neural Tube Defect — United States, 1997–2009
Preventing the recurrence of NTDs by managing maternal risk factors before conception, including folic acid intake and obesity, presents important opportunities for public health.
Updated Estimates of Neural Tube Defects Prevented by Mandatory Folic Acid Fortification — United States, 1995–2011
The updated estimate of approximately 1,300 NTD-affected births averted annually during the post-fortification period is slightly higher than the previously published estimate. Mandatory folic acid fortification remains an effective public health policy intervention.
Avoid Harmful Substances
Make a PACT to get healthy, physically and mentally, before and during pregnancy to increase your chances of having a healthy baby. Avoiding harmful home and workplace exposures is one important step.
Get Tested: National HIV and STD Testing
Find free, fast, and confidential testing near you. Also, find what test you need.
Are Flight Attendants at Higher Risk for Miscarriage?
Working during normal sleep hours, high physical job demands and exposure to cosmic radiation may put pregnant flight attendants at higher risk for miscarriage, according to research published January 5 online in the journal Epidemiology.
Mortality in the United States, 2013
Life expectancy for the U.S. population in 2013 was unchanged from 2012 at 78.8 years. In 2013, life expectancy was 81.2 years for females and 76.4 for males.
Inside Knowledge: Get the Facts About Gynecologic Cancer
The Inside Knowledge campaign raises awareness of the five main types of gynecologic cancer: cervical, ovarian, uterine, vaginal, and vulvar. Inside Knowledge encourages women to pay attention to their bodies, so they can recognize any warning signs and seek medical care.
Cervical Cancer Awareness
No woman should die of cervical cancer. The most important thing you can do to help prevent cervical cancer is to get screened regularly starting at age 21.
Folic Acid & Birth Defects
Get healthy before and during pregnancy to increase your chances of having a healthy baby. You can plan ahead by getting enough folic acid each day.
Lung Obstruction Among Adults Aged 40–79: United States, 2007–2012
A similar percentage of men and women had lung obstruction, overall and at each level of severity.
Protect Your Daughters from Cervical Cancer
HPV vaccine can prevent several types of cancers, including cervical cancer. Get HPV vaccine for your sons and daughters at ages 11-12 to protect them from HPV cancers including cervical cancer.
Reported STDs in the United States
This fact sheet summarizes 2013 data on chlamydia, gonorrhea, and syphilis published in CDC’s annual report, Sexually Transmitted Disease Surveillance, 2013.
Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003–2012
Prescription cholesterol-lowering medication use increased with age, from 17.4% in adults aged 40–59 to 43.3% in adults aged 60–74 and 47.6% in adults aged 75 and over. There was no significant difference between men (30.1%) and women (26.2%) or any race and Hispanic origin groups (24.1%–28.9%).

CDC Funding

Snapshots

thumbnail
thumbnail
thumbnail

Federal Agency News

National, State and Local News

Global

CDC Podcasts
Listen to the latest podcasts on women’s health.
CDC E-Cards
Send women’s health e-cards.
Publicado por en No hay comentarios:

Pregnancy and High Blood Pressure: MedlinePlus Health News Video

Pregnancy and High Blood Pressure: MedlinePlus Health News Video

A service of the U.S. National Library of Medicine
From the National Institutes of HealthNational Institutes of Health



01/29/2015 09:27 AM EST


Source: HealthDay - Video
Related MedlinePlus Page: High Blood Pressure in Pregnancy
Publicado por en No hay comentarios:

Press Announcements > FDA takes steps to improve reliability of automated external defibrillators

Press Announcements > FDA takes steps to improve reliability of automated external defibrillators



FDA takes steps to improve reliability of automated external defibrillators

For Immediate Release

January 28, 2015

Release

The U.S. Food and Drug Administration announced today that it will strengthen its review of automated external defibrillators (AEDs) to help improve the quality and reliability of these devices.
The FDA issued a final order that will require AED manufacturers to submit premarket approval applications (PMAs), which undergo a more rigorous review than what was required to market these devices in the past. The agency’s strengthened review will focus on the critical requirements needed to ensure the safety and reliability of AEDs and their necessary accessories, including batteries, pad electrodes, adapters and hardware keys for pediatric use.
“Automated external defibrillators save lives,” said William Maisel, M.D., M.P.H, deputy director for science, chief scientist and acting director of the Office of Device Evaluation in the FDA’s Center for Devices and Radiological Health. “These changes to the way these devices are reviewed will allow us to more closely monitor how they are designed and manufactured. This will go a long way towards correcting long-standing problems and ultimately improving the reliability of these devices.”
Automated external defibrillators are portable, electronic medical devices that automatically sense potentially life-threatening cardiac arrhythmias and either automatically deliver or advise the user to deliver electrical stimulation to re-establish normal heart rhythms. They are often stored in public locations for use in an emergency and, while they can be lifesaving, there has been a history of malfunction issues.
From January 2005 through September 2014, the FDA received approximately 72,000 medical device reports associated with the failure of these devices. Since 2005, manufacturers have conducted 111 recalls, affecting more than two million AEDs. The problems associated with many of these recalls and reports included design and manufacturing issues, such as inadequate control of components purchased from other suppliers.
By requiring premarket approval for these devices, the FDA will receive important information about an AED manufacturer’s quality systems information. The FDA will also conduct inspections of manufacturers’ facilities prior to approval. After approval, manufacturers will be required to submit to the FDA any changes made to the devices that affect safety or effectiveness, and annual reports on device performance.
Given the importance of these devices in emergency situations, AEDs currently on the market will remain available while manufacturers work to meet the new PMA requirements. The FDA does not intend to enforce the PMA requirement for AEDs until July 29, 2016, as long as manufacturers notify the FDA of their intent to file a PMA by April 29, 2015. The FDA does not intend to enforce the PMA requirement for currently marketed, necessary AED accessories until January 29, 2020.
The Food and Drug Administration Safety and Innovation Act calls for the FDA to publish proposed and final orders to reclassify or call for PMAs for pre-amendments devices. The FDA’s Circulatory System Devices Panel recommended that AEDs remain Class III medical devices and require PMAs. The FDA originally issued a proposed order in March 2013 calling for PMAs to ensure the appropriate regulation of Class III pre-amendments devices.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Publicado por en No hay comentarios:

Do Pregnant Women Need High Blood Pressure Treatment?: MedlinePlus

Do Pregnant Women Need High Blood Pressure Treatment?: MedlinePlus

A service of the U.S. National Library of Medicine
From the National Institutes of HealthNational Institutes of Health





Do Pregnant Women Need High Blood Pressure Treatment?

Controlling blood pressure doesn't seem to affect baby, but may prevent problems for mom
Wednesday, January 28, 2015
HealthDay news image
Related MedlinePlus Page
WEDNESDAY, Jan. 28, 2015 (HealthDay News) -- When pregnant women have high blood pressure, more-intensive treatment doesn't seem to affect their babies, but it may lower the odds that moms will develop severely high blood pressure.
That's the conclusion of a clinical trial reported in the Jan. 29 issue of the New England Journal of Medicine.
Experts were divided, however, on how to interpret the results.
For one of the study's authors, the choice is clear. Tighter blood pressure control, aiming to get women's numbers "normalized," is better, said the study's lead researcher, Dr. Laura Magee, of the Child and Family Research Institute and the University of British Columbia in Vancouver, Canada.
"If less-tight control had no benefit for the baby, then how do you justify the risk of severe (high blood pressure) in the mother?" said Magee.
But current international guidelines on managing high blood pressure in pregnancy vary. And the advice from the American College of Obstetricians and Gynecologists (ACOG) is consistent with the "less-tight" approach, according to Dr. James Martin, a past president of ACOG.
To him, the new findings support that guidance. "Tighter blood pressure control doesn't seem to make much difference," said Martin, who recently retired as director of maternal-fetal medicine at the University of Mississippi Medical Center.
"This basically suggests we don't have to change what we're already doing," Martin said.
High blood pressure, or hypertension, is the most common medical condition of pregnancy -- affecting about 10 percent of pregnant women, according to Magee's team. Some of those women go into pregnancy with the condition, but many more develop pregnancy-induced hypertension, which arises after the 20th week.
Magee said the long-standing question has been whether doctors should try to "normalize" women's blood pressure numbers -- as they would with a patient who wasn't pregnant -- or be less aggressive.
The worry, Martin explained, is that lowering a pregnant woman's blood pressure too much could reduce blood flow to the placenta and impair fetal growth. Some studies have found that to be a risk.
But in this trial, the degree of blood pressure control did not affect a woman's risk of pregnancy loss or having a baby who needed a stay in the newborn intensive care unit, Magee said.
The findings are based on nearly 1,000 pregnant women from 16 different countries who had high blood pressure. Half were randomly assigned to "tight" blood pressure control, and half to "less tight."
High blood pressure is defined as above 140/90 mm Hg. For the tight-control group, the goal was to get that second number (the diastolic pressure) to 85 or lower; for the less-tight group, the goal was 100 or lower, according to the study.
Treatment involved regular blood pressure checks and, for most women, medication -- with the dose adjusted when needed. Usually, women took a drug called labetalol, which is the blood pressure medication most commonly used during pregnancy.
In the end, Magee's team found no differences in how the two groups fared, except for one: Almost 41 percent of women under looser blood pressure control eventually developed severe high blood pressure (a reading of 160/110 mm Hg or higher), while just 27.5 percent of women on the tighter regimen developed severe high blood pressure.
Severe high blood pressure can generally be quickly brought down with IV medication, Martin said. The main concern is that it can lead to a stroke in some women.
But, that didn't happen in this trial to women with higher blood pressure. However, one woman on the stricter treatment regimen had a stroke.
Martin noted that the less-aggressive approach can be easier for women, with less blood pressure monitoring at home and the doctor's office.
However, Magee said she believes the risk of severely high numbers is not acceptable if less-intensive treatment has no clear benefit for babies.
"Before this study, I was for less-tight control," she noted. "Now I've changed my practice."
Until now, studies on this issue have been small or lower-quality, according to Magee. She said current professional guidelines vary because of that lack of strong evidence.
For now, both Magee and Martin encouraged pregnant women with high blood pressure to keep up with their doctor visits and stick with a treatment plan. But Magee suggested advocating for tighter blood pressure control.
She noted that more evidence on the issue will be coming. Another major clinical trial -- called the Chronic Hypertension and Pregnancy Project -- is set to get underway in U.S. hospitals soon.
SOURCES: Laura Magee, M.D., senior clinician scientist, Child and Family Research Institute, clinical professor, medicine, University of British Columbia, Vancouver; James Martin, M.D., past president, American College of Obstetricians and Gynecologists; Jan. 29, 2015, New England Journal of Medicine
HealthDay
Copyright (c) 2015 HealthDay. All rights reserved.
Publicado por en No hay comentarios:

Ebola Vaccine Appears Safe, Triggers Immune Response, U.K. Study Finds: MedlinePlus

Ebola Vaccine Appears Safe, Triggers Immune Response, U.K. Study Finds: MedlinePlus

A service of the U.S. National Library of Medicine
From the National Institutes of HealthNational Institutes of Health







Ebola Vaccine Appears Safe, Triggers Immune Response, U.K. Study Finds

Early trial findings echo those from a smaller U.S. study
By Robert Preidt
Wednesday, January 28, 2015
HealthDay news image
Related MedlinePlus Page
WEDNESDAY, Jan. 28, 2015 (HealthDay News) -- Early results suggest an experimental Ebola vaccine triggers an immune response and is safe to use.
However, larger clinical trials in West Africa are needed to determine if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the U.K.
This vaccine works against the Zaire strain of Ebola currently circulating in West Africa. It doesn't contain infectious Ebola virus material, so it cannot cause Ebola infection in people who receive it.
The vaccine is being developed by the U.S. National Institutes of Health and GlaxoSmithKline. The first doses of the vaccine for use in large clinical trials in West Africa have been delivered to Liberia.
The Oxford University trial included 60 healthy volunteers who were monitored for 28 days after receiving three different doses of the vaccine. The volunteers will continue to be monitored for six months.
"The vaccine was well tolerated. Its safety profile is pretty much as we had hoped," clinical trial leader Adrian Hill said in a university news release.
"People typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish," Hill said. "It's very similar to what has been seen in previous studies with this general type of vaccine."
The findings were published Jan. 28 in the New England Journal of Medicine.
A trial of 20 people in the United States generated similar findings. That study's results were published last November, also in the New England Journal of Medicine.
The Oxford trial is one of several safety trials of the experimental vaccine that have been fast-tracked in the United States, England, Mali and Switzerland.
The Oxford team said it has also started testing an experimental booster vaccine against Ebola to determine if it can enhance the immune response after initial vaccination.
West Africa's Ebola epidemic has slowed significantly, but health officials are hesitant to say the lethal virus is no longer a threat.
Ebola infections have killed more than 8,600 people and sickened 21,000, mostly in the countries of Liberia, Sierra Leone and Guinea since cases first surfaced in Guinea last winter. Infections in all three countries have dropped in recent months, with Liberia experiencing the greatest falloff, the World Health Organization and others have reported in recent days.
SOURCE: Oxford University, news release, Jan. 28, 2015
HealthDay
Copyright (c) 2015 HealthDay. All rights reserved.
More Health News on:
Ebola
Publicado por en No hay comentarios:
Suscribirse a: Entradas (Atom)